5,503 Shares in Medpace Holdings, Inc. $MEDP Acquired by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP acquired 5,503 Medpace shares worth approximately $2.9 million in the second quarter. Institutional investors collectively own 77.98% of the company.
• Medpace directors sold shares recently, including transactions totaling more than $7.4 million, while insiders sold 134,471 shares valued at approximately $82.2 million over the past 90 days.
• Medpace beat quarterly earnings and revenue estimates, reporting $4.25 EPS and $707.33 million in revenue, up 17.2% year over year. Despite some bullish analyst updates, the overall Wall Street consensus remains “Hold” with a $584.18 price target.

Corient Private Wealth LP acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 5,503 shares of the company's stock, valued at approximately $2,914,000.

Several other institutional investors also recently bought and sold shares of the stock. Johnson Financial Group Inc. bought a new position in shares of Medpace in the second quarter worth approximately $27,000. Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after buying an additional 37 shares during the period. Elyxium Wealth LLC bought a new position in shares of Medpace during the fourth quarter valued at approximately $30,000. Jones Financial Companies Lllp bought a new position in shares of Medpace during the second quarter valued at approximately $30,000. Finally, Allied Private Wealth LLC purchased a new stake in Medpace in the second quarter worth $31,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Medpace

In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of Medpace stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total value of $4,414,590.45. Following the completion of the sale, the director owned 3,798 shares of the company's stock, valued at $2,302,157.70. The trade was a 65.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Brian T. Carley sold 5,000 shares of the company's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company's stock, valued at approximately $16,935,129.75. This trade represents a 15.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 134,471 shares of company stock valued at $82,151,311 over the last 90 days. 20.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Weiss Ratings raised Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Truist Financial upped their target price on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Mizuho increased their target price on Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Finally, TD Cowen raised their target price on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat, Medpace has a consensus rating of "Hold" and a consensus price target of $584.18.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $583.21 on Wednesday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The company has a market cap of $16.28 billion, a P/E ratio of 34.19, a PEG ratio of 2.65 and a beta of 1.15. The stock's fifty day moving average price is $570.29 and its 200-day moving average price is $496.46.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the firm earned $3.10 earnings per share. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source